Bonnie Kwan
Nurse Practitioner · Las Vegas, NVNPI 1891294732
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,036 of the $30,253 with a category attached, or 69.5%. It is spread thinly across 37 manufacturers, the largest accounting for just 15.0%. 2025 is the largest year on record at $9,489, 3.1 times the $3,019 reported in 2021. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 836 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Organon$4K
- Boehringer Ingelheim$3K
- Arcutis Biotherapeutics, Inc.$3K
- UCB, Inc.$3K
- Sanofi$2K
- plus $12K from 31 others
What the payments were for
- Consulting fees$6,21021%
- Travel & lodging$2,4588%
- Food & beverage$21,03670%
- Education$5492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 147 | $4,537 |
| Organon | 16 | $3,898 |
| Boehringer Ingelheim | 9 | $3,155 |
| Arcutis Biotherapeutics, Inc. | 53 | $2,718 |
| UCB, Inc. | 47 | $2,665 |
| Sanofi | 38 | $1,719 |
| Dermavant Sciences, Inc. | 45 | $1,693 |
| E.r. Squibb & Sons, L.L.C. | 175 | $1,166 |
| Johnson & Johnson | 56 | $1,160 |
| Sun Pharmaceutical Industries Inc. | 31 | $1,025 |
| Amgen | 37 | $957 |
| Pfizer | 40 | $764 |
| Galderma Laboratories, L.p. | 17 | $762 |
| LEO Pharma Inc. | 28 | $725 |
| Journey Medical Corporation | 5 | $466 |
| Lilly USA, LLC | 15 | $431 |
| Incyte Corporation | 13 | $350 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $309 |
| Regeneron Healthcare Solutions, Inc. | 10 | $304 |
| Novartis | 9 | $250 |
| Merz North America, Inc. | 4 | $207 |
| VYNE Pharmaceuticals Inc. | 2 | $153 |
| Revance Therapeutics, Inc. | 2 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| CSL Behring | 5 | $123 |
| GSK | 4 | $112 |
| Octapharma USA, Inc. | 5 | $78 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $70 |
| Boston Scientific | 3 | $48 |
| AstraZeneca | 2 | $27 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Sandoz | 1 | $13 |
| Pharming Healthcare, Inc. | 1 | $12 |
| Biofrontera Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,253 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 24 | $496,498 |
| Humira(Cf) PenAdalimumab | 26 | $200,417 |
| Dupixent PenDupilumab | 40 | $156,810 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $148,736 |
| OtezlaApremilast | 24 | $130,123 |
| OpzeluraRuxolitinib Phosphate | 26 | $49,356 |
| VtamaTapinarof | 11 | $14,885 |
| Tacrolimus | 67 | $9,956 |
| Clobetasol Propionate | 209 | $7,390 |
| Ketoconazole | 346 | $5,401 |
| Triamcinolone Acetonide | 401 | $4,351 |
| Mometasone Furoate | 192 | $4,095 |
| Clindamycin Phosphate | 104 | $3,642 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 91 | $3,135 |
| Ammonium Lactate | 143 | $2,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $957 | $130,12324 claims |
| Incyte CorporationOpzelura | $350 | $49,35626 claims |
| Dermavant Sciences, Inc.Vtama | $1,693 | $14,88511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Las Vegas
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
- Katherine WhitmireLas Vegas$18K
- Jennifer WalshLas Vegas$18K
- Andrew VolinLas Vegas$17K
- John BlakemoreLas Vegas$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.